Chronic Kidney Disease (CKD) Drugs Market Size, Share, Trends, Growth Outlook

Chronic Kidney Disease (CKD) Drugs Market is estimated to increase at a growth rate of 6.3% CAGR over the forecast period from 2024 to 2030.

The global Chronic Kidney Disease (CKD) Drugs Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Drug Class (Erythropoietin stimulating agents, Calcium channel blockers, Phosphate binders, ACE inhibitors, Others), By Route of Administration (Oral, Subcutaneous, Intravenous).

An Introduction to Chronic Kidney Disease (CKD) Drugs Market in 2024

The Chronic Kidney Disease (CKD) Drugs Market comprises pharmaceuticals, renal therapies, dialysis medications, and nephroprotective agents developed to manage chronic kidney disease stages, renal complications, and associated comorbidities such as hypertension, anemia, and mineral bone disorders. These drugs include erythropoiesis-stimulating agents (ESAs), phosphate binders, vitamin D analogs, antihypertensives, and diuretics, aiming to slow disease progression, preserve kidney function, and prevent cardiovascular complications in CKD patients. In 2024, this market emphasizes innovative renal drug classes, precision medicine approaches, targeted therapies, and patient-centered care strategies, optimizing renal health outcomes and quality of life for individuals with chronic kidney disease.

Chronic Kidney Disease (CKD) Drugs Market Competitive Landscape

The global Chronic Kidney Disease (CKD) Drugs Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Chronic Kidney Disease (CKD) Drugs Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Chronic Kidney Disease (CKD) Drugs Industry include- AbbVie Inc, Akebia Therapeutics Inc, Amgen Inc, AstraZeneca Plc, Bayer AG, Biogen Inc, Boehringer Ingelheim International GmbH, Cara Therapeutics Inc, Eli Lilly and Co., F. Hoffmann La Roche Ltd, FibroGen Inc, Horizon Therapeutics Plc, Johnson and Johnson, Kissei Pharmaceutical Co. Ltd, Novartis AG, OPKO Health Inc, Pfizer Inc, Pharmacosmos AS, Rockwell Medical Inc, Sanofi SA.

Chronic Kidney Disease Drugs Market Trend: Focus on Disease Modification and Renal Protection

A prominent trend in the chronic kidney disease (CKD) drugs market is the focus on disease modification and renal protection in the development of novel therapeutics. With the rising global prevalence of CKD and its associated complications, there is growing emphasis on developing drugs that not only alleviate symptoms but also slow disease progression, preserve renal function, and reduce the risk of adverse outcomes such as end-stage renal disease (ESRD) and cardiovascular events. This trend encompasses research into renoprotective agents, antifibrotic therapies, and innovative drug delivery technologies aimed at targeting underlying pathophysiological mechanisms and addressing unmet medical needs in CKD management.

Chronic Kidney Disease Drugs Market Driver: Growing Burden of Chronic Kidney Disease and End-Stage Renal Disease

A key driver propelling the chronic kidney disease drugs market is the growing burden of CKD and end-stage renal disease (ESRD) worldwide. Factors such as aging populations, rising prevalence of diabetes and hypertension, and lifestyle-related risk factors contribute to the increasing incidence and progression of CKD, necessitating effective pharmacological interventions to slow disease progression and improve patient outcomes. Additionally, the economic and clinical burden of ESRD, including the need for dialysis or kidney transplantation, underscores the importance of early intervention and effective management strategies to delay disease progression, reduce complications, and optimize quality of life for individuals living with CKD.

Chronic Kidney Disease Drugs Market Opportunity: Expansion of Therapeutic Options for Advanced CKD and ESRD

An emerging opportunity in the chronic kidney disease drugs market lies in the expansion of therapeutic options for advanced CKD and ESRD. While current treatment strategies focus on slowing disease progression and managing complications in early stages of CKD, there remains a need for effective therapies that address the unique challenges and complexities associated with advanced CKD and ESRD. Pharmaceutical companies and research institutions have the opportunity to innovate in the development of novel drugs targeting key pathways involved in renal fibrosis, inflammation, oxidative stress, and uremic toxin accumulation, with the aim of improving outcomes, reducing morbidity and mortality, and enhancing quality of life for patients at advanced stages of CKD. By investing in research and development efforts focused on advanced CKD and ESRD therapeutics, stakeholders can address unmet medical needs and advance the standard of care for individuals with advanced renal disease.

Market Share Analysis: Erythropoietin Stimulating Agents is the fastest growing segment in the Chronic Kidney Disease Drugs industry

Among chronic kidney disease (CKD) drugs, erythropoietin stimulating agents (ESAs) are experiencing significant growth. CKD is a progressive condition characterized by the gradual loss of kidney function over time. Anemia commonly accompanies CKD due to decreased production of erythropoietin, a hormone produced by the kidneys that stimulates red blood cell production. ESAs, such as erythropoietin and darbepoetin alfa, are synthetic forms of erythropoietin that stimulate the bone marrow to produce more red blood cells, thereby alleviating anemia associated with CKD. As the prevalence of CKD continues to rise globally, driven by factors such as aging populations and the increasing incidence of conditions like diabetes and hypertension, the demand for ESAs is expected to grow. Additionally, advancements in ESA formulations and delivery methods, such as extended-release formulations and subcutaneous administration, have improved treatment convenience and adherence for patients with CKD-related anemia. Healthcare providers are increasingly utilizing ESAs as part of comprehensive management strategies for CKD, highlighting their importance in improving patients' quality of life and reducing the risk of complications associated with anemia and CKD progression.

Chronic Kidney Disease (CKD) Drugs Market Segmentation

By Drug Class
Erythropoietin stimulating agents
Calcium channel blockers
Phosphate binders
ACE inhibitors
Others
By Route of Administration
Oral
Subcutaneous
Intravenous
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Chronic Kidney Disease (CKD) Drugs Companies

AbbVie Inc
Akebia Therapeutics Inc
Amgen Inc
AstraZeneca Plc
Bayer AG
Biogen Inc
Boehringer Ingelheim International GmbH
Cara Therapeutics Inc
Eli Lilly and Co.
F. Hoffmann La Roche Ltd
FibroGen Inc
Horizon Therapeutics Plc
Johnson and Johnson
Kissei Pharmaceutical Co. Ltd
Novartis AG
OPKO Health Inc
Pfizer Inc
Pharmacosmos AS
Rockwell Medical Inc
Sanofi SA
* List not Exhaustive

Reasons to Buy the Chronic Kidney Disease (CKD) Drugs Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Chronic Kidney Disease (CKD) Drugs Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Chronic Kidney Disease (CKD) Drugs Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Chronic Kidney Disease (CKD) Drugs Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Chronic Kidney Disease (CKD) Drugs Market Size Outlook, $ Million, 2021 to 2030
3.2 Chronic Kidney Disease (CKD) Drugs Market Outlook by Type, $ Million, 2021 to 2030
3.3 Chronic Kidney Disease (CKD) Drugs Market Outlook by Product, $ Million, 2021 to 2030
3.4 Chronic Kidney Disease (CKD) Drugs Market Outlook by Application, $ Million, 2021 to 2030
3.5 Chronic Kidney Disease (CKD) Drugs Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Chronic Kidney Disease (CKD) Drugs Industry
4.2 Key Market Trends in Chronic Kidney Disease (CKD) Drugs Industry
4.3 Potential Opportunities in Chronic Kidney Disease (CKD) Drugs Industry
4.4 Key Challenges in Chronic Kidney Disease (CKD) Drugs Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Chronic Kidney Disease (CKD) Drugs Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Chronic Kidney Disease (CKD) Drugs Market Outlook by Segments
7.1 Chronic Kidney Disease (CKD) Drugs Market Outlook by Segments, $ Million, 2021- 2030
By Drug Class
Erythropoietin stimulating agents
Calcium channel blockers
Phosphate binders
ACE inhibitors
Others
By Route of Administration
Oral
Subcutaneous
Intravenous
8 North America Chronic Kidney Disease (CKD) Drugs Market Analysis and Outlook To 2030
8.1 Introduction to North America Chronic Kidney Disease (CKD) Drugs Markets in 2024
8.2 North America Chronic Kidney Disease (CKD) Drugs Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Chronic Kidney Disease (CKD) Drugs Market size Outlook by Segments, 2021-2030
By Drug Class
Erythropoietin stimulating agents
Calcium channel blockers
Phosphate binders
ACE inhibitors
Others
By Route of Administration
Oral
Subcutaneous
Intravenous
9 Europe Chronic Kidney Disease (CKD) Drugs Market Analysis and Outlook To 2030
9.1 Introduction to Europe Chronic Kidney Disease (CKD) Drugs Markets in 2024
9.2 Europe Chronic Kidney Disease (CKD) Drugs Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Chronic Kidney Disease (CKD) Drugs Market Size Outlook by Segments, 2021-2030
By Drug Class
Erythropoietin stimulating agents
Calcium channel blockers
Phosphate binders
ACE inhibitors
Others
By Route of Administration
Oral
Subcutaneous
Intravenous
10 Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Chronic Kidney Disease (CKD) Drugs Markets in 2024
10.2 Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Chronic Kidney Disease (CKD) Drugs Market size Outlook by Segments, 2021-2030
By Drug Class
Erythropoietin stimulating agents
Calcium channel blockers
Phosphate binders
ACE inhibitors
Others
By Route of Administration
Oral
Subcutaneous
Intravenous
11 South America Chronic Kidney Disease (CKD) Drugs Market Analysis and Outlook To 2030
11.1 Introduction to South America Chronic Kidney Disease (CKD) Drugs Markets in 2024
11.2 South America Chronic Kidney Disease (CKD) Drugs Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Chronic Kidney Disease (CKD) Drugs Market size Outlook by Segments, 2021-2030
By Drug Class
Erythropoietin stimulating agents
Calcium channel blockers
Phosphate binders
ACE inhibitors
Others
By Route of Administration
Oral
Subcutaneous
Intravenous
12 Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Chronic Kidney Disease (CKD) Drugs Markets in 2024
12.2 Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market size Outlook by Segments, 2021-2030
By Drug Class
Erythropoietin stimulating agents
Calcium channel blockers
Phosphate binders
ACE inhibitors
Others
By Route of Administration
Oral
Subcutaneous
Intravenous
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
Akebia Therapeutics Inc
Amgen Inc
AstraZeneca Plc
Bayer AG
Biogen Inc
Boehringer Ingelheim International GmbH
Cara Therapeutics Inc
Eli Lilly and Co.
F. Hoffmann La Roche Ltd
FibroGen Inc
Horizon Therapeutics Plc
Johnson and Johnson
Kissei Pharmaceutical Co. Ltd
Novartis AG
OPKO Health Inc
Pfizer Inc
Pharmacosmos AS
Rockwell Medical Inc
Sanofi SA
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Drug Class
Erythropoietin stimulating agents
Calcium channel blockers
Phosphate binders
ACE inhibitors
Others
By Route of Administration
Oral
Subcutaneous
Intravenous